For Elan Investors, A Choice Between A Sure Thing Or A High-Risk Play
This article was originally published in The Pink Sheet Daily
Executive Summary
Royalty Pharma’s $11 per-share bid for Elan is too low, according to Elan’s management and industry analysts. But will investors, anxious about the company’s planned buying spree, opt for a certain exit or trust management to execute the long-term strategy?